Pyrazole Derivatives Inhibiting PARP Activity
Solution Overview
Problem
Current treatments for diseases mediated by poly(ADP-ribose) polymerase (PARP) lack effective inhibitors that can specifically target and modulate its activity, leading to uncontrolled enzyme activation and subsequent cellular damage or apoptosis.
Innovation Solution
Development of a compound of general formula (I) and its derivatives, which are designed to inhibit PARP activity by reacting specific compounds to form a pharmaceutical composition that can be administered to inhibit PARP enzymatic functions, thereby treating conditions associated with excessive PARP activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PARP is activated to repair DNA damage, then cell survival and chromosome stability are improved, but excessive PARP activation consumes NAD and ATP leading to cell energy deficiency and apoptosis
Solution Approach 1:
The patent develops compounds that modulate PARP activity by changing the enzymatic parameter state, preventing excessive activation while maintaining necessary repair functions. The compounds alter the activation threshold and activity level of PARP, ensuring it operates within optimal energy-consuming ranges that support DNA repair without depleting cellular NAD and ATP reserves.
Solution Approach 2:
The invention creates a regulatory feedback mechanism where the compounds monitor and respond to PARP activation levels. When DNA damage occurs, the compounds allow appropriate PARP activation for repair, but when activation becomes excessive and threatens cellular energy balance, the compounds intervene to suppress further activation, thus preventing the harmful feedback loop of uncontrolled PARP activity.
2Reliability
If current treatments are used for PARP-mediated diseases, then disease management is attempted, but effective inhibition of PARP activity is not achieved leading to uncontrolled enzyme activation
Solution Approach 1:
The patent introduces compound (I) as an intermediary substance that mediates between the disease state and PARP enzyme activity. These compounds specifically bind to PARP or its regulatory elements, acting as molecular mediators that translate therapeutic intent into controlled enzyme inhibition, thereby preventing uncontrolled activation while maintaining necessary physiological functions.
Solution Approach 2:
The compounds change the kinetic and regulatory parameters of PARP activity, altering substrate binding affinity, catalytic rate, or allosteric regulation characteristics. This parameter modification enables precise control over PARP activation thresholds and activity levels, achieving effective disease treatment while preventing harmful uncontrolled enzyme activation.
Data Source
AI summary
Disclosed are compounds of general formula (I), wherein R, R1, Rc, Rd, Re, Rf, X, Y, Z, A and B are as defined in the application.